Actively controlled local drug delivery using conductive polymer-based devices
Actively controlled local drug delivery using conductive polymer-based devices
复制标题
使用基于导电聚合物的装置主动控制局部药物输送
DOI：
10.1063/1.5138587
复制
发表时间：
2020-01-06
影响因子：
4
通讯作者：
Green, Rylie A.
中科院分区：
文献类型：
--
作者：
Chapman, Christopher A. R.;Cuttaz, Estelle A.;Green, Rylie A.
局部和主动控制的药物输送为提高生物利用度、治疗效果和损伤或疾病的长期治疗提供了机会。基于导电聚合物 (CP) 的系统为利用固有的电化学和驱动特性提供了独特的机会，以确保使用电荷控制机制输送或保留药物。人们已经探索了许多 CP 格式，包括 CP 薄膜、CP 与聚合物载体的复合材料以及有机电子离子泵 (OEIP)。这些设计中的每一种都可用于输送具有离子特性的药物，这些药物在电脉冲或循环过程中利用 CP 的掺杂和去掺杂特性。然而，使用驱动和 OEIP 的 CP 复合材料是新兴技术，可以更好地满足输送具有不同净电荷特性的各种药物的需求。这些系统还允许高载药量，并且通过适当的配置，它们可以使用额外的电极将药物驱动到组织中。在输送具有不同电荷特性的多种药物类型方面也存在创新机会，可以单独解决。基于 CP 的药物输送系统的未来将受到转化挑战的强烈影响，包括在临床使用这些新型材料平台之前需要获得监管部门的批准。多学科合作对于推动技术发展和创建个性化生物电子疗法的新范例至关重要。
Localized and actively controlled delivery of drugs presents an opportunity for improving bioavailability, therapeutic efficacy, and long-term treatment of injury or disease. Conductive polymer (CP) based systems present a unique opportunity for using inherent electrochemical and actuating properties to ensure that drugs are delivered or retained using charge controlled mechanisms. A number of CP formats have been explored spanning CP films, composites of CPs with polymeric carriers, and organic electronic ion pumps (OEIPs). Each of these designs can be used to deliver drugs with ionic properties that take advantage of the doping and dedoping characteristics of CPs during electrical pulsing or cycling. However, CP composites that use actuation and OEIPs are emerging technologies that can better address the need for the delivery of a wide range of drugs with varying net charge properties. These systems also allow a high drug loading profile, and with an appropriate configuration, they can use additional electrodes to drive drugs into the tissues. There are also innovative opportunities in the delivery of multiple drug types with varying charge properties that can be individually addressed. The future of CP based drug delivery systems will be strongly influenced by translational challenges including the need for regulatory approvals prior to the use of these novel material platforms in the clinic. Multidisciplinary collaboration will be critical to driving technology development and creating a new paradigm in personalized bioelectronic delivery of therapeutics.